Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 2/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.30 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2191872 | 0.73 | PDK2 (0.41) | PDK2 | |
| SCHEMBL5594716 | 0.68 | RAD52 (0.45) | MEN1KMT2A | |
| SCHEMBL8207862 | 0.68 | ACHE (0.39) | PDK2ACHEHCAR2HDAC4MEN1 | |
| SCHEMBL14392692 | 0.67 | PDK2 (0.39) | PDK2MEN1KMT2A | |
| SCHEMBL15427821 | 0.67 | PDK2 (0.36) | PDK2ACHEBACE1HCAR3HCAR2 | |
| SCHEMBL7768071 | 0.65 | PGR (0.31) | HCAR2PGR | |
| SCHEMBL22236873 | 0.65 | PDK2 (0.39) | PDK2ACHEBACE1HCAR3HCAR2 | |
| SCHEMBL23448749 | 0.64 | PDK2 (0.34) | PDK2ACHEBACE1HCAR3HCAR2 | |
| SCHEMBL20023635 | 0.64 | PDK2 (0.55) | PDK2AKR1B1ACHEBACE1AKR1A1 | |
| SCHEMBL13686011 | 0.62 | BACE1 (0.38) | PDK2ACHEBACE1HCAR3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110196012-A1 | DEUTERATED MACROCYCLIC INHIBITORS OF VIRAL NS3 PROTEASE | CONCERT PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110196012-A1 | DEUTERATED MACROCYCLIC INHIBITORS OF VIRAL NS3 PROTEASE | DPP3, SPINT2, DPP4 | PDK2 2715/4885AKR1B1 2752/4885ACHE 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.